Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Med Epigenet. 2014 Feb 14;2(1):28–36. doi: 10.1159/000358882

Fig. 1.

Fig. 1

Performance of Active Motif, Epitect+, Zymo Methylation, Zymo Gold and Zymo Lightning kits according to the respective manufacturer’s protocols (individual A). ALUSX, IGF2, IL6ST and ST3GAL2 methylation (%) estimates assessed on human whole-blood DNA from individual A using the Epitect+, MethylDetector, Zymo Gold, Zymo Lightning and Zymo Methylation kits according to the manufacturer’s protocols. Data are reported as mean of two different bisulfite treatments after which two technical replicates have been performed (SD across bisulfite and technical replicates was <5% for each of the CpG sites analyzed).